Clinical trials: Obstructive Pulmonary Disease
Asthma
Chronic-Dose Safety and Efficacy Study of Albuterol-HFA-BAI in Pediatric Asthmatics
This study is designed to evaluate the repeat-dose safety and effectiveness of a bronchodilator inhaler relative to placebo (inactive drug inhaler) in children aged 4-11 years with asthma.
- Trial name
- NCT00308685
- Testing
- Albuterol
- Where
- 14 sites in United States
- Volunteers
- 95 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Three Doses of Aclidinium Bromide Compared to Placebo and to an Active Comparator in Chronic Obstructive Pulmonary Disease (COPD) Patients.
The present trial is conducted to further assess the efficacy by means of serial spirometry, safety and tolerability of three doses of aclidinium bromide administered twice a day compared to previously approved BID drug…
- Trial name
- NCT01120093
- Testing
- Aclidinium bromide 100 μg bid, Aclidinium bromide 200 μg bid, Aclidininum bromide 400 μg bid
- Where
- 11 sites in Belgium, Germany
- Volunteers
- 79 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study will evaluate the safety and efficacy of QVA149 in patients with moderate to severe COPD.
- Trial name
- NCT00570778
- Testing
- indacaterol/glycopyrrolate, indacaterol
- Where
- 22 sites in United States, Belgium and 3 more
- Volunteers
- 154 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma
The primary objective of this trial is to evaluate the safety and efficacy of two doses of tiotropium inhalation solution delivered via the Respimat® inhaler once daily in the afternoon in patients (1 to 5 years old) with…
- Trial name
- NCT01634113
- Testing
- tiotropium-bromide
- Where
- 33 sites in United States, Belgium and 9 more
- Volunteers
- 102 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Study of Inhaler Device Attributes Investigating Critical and Overall Errors, Ease of Use, and Preference Between a Number of Inhaler Devices
This is a randomised, open-label, placebo, crossover, multicentre study with a single visit. The study will comprise five sub-studies.
- Trial name
- NCT02184624
- Testing
- ELLIPTA, DISKUS/ACCUHALER, MDI
- Where
- 8 sites in Netherlands, United Kingdom
- Volunteers
- 569 people
- Sponsor
- GlaxoSmithKline
Asthma
Health Effects of Diesel Exhaust in Asthmatic Patients: A Real-world Study in a London Street
Acute exposure to diesel exhaust under normal city conditions leads to a worsening of symptoms of asthma, with reduction in lung function in asthmatic nonsmoking adults, dependent on the exposure dose and on the background…
- Trial name
- NCT00127062
- Testing
- Oxford street, Hyde park
- Volunteers
- 60 people
- Sponsor
- Imperial College London
Pulmonary Disease, Chronic Obstructive
A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking Albuterol/Salbutamol and Ipratropium
The objective of this study is to assess the daily variation in bronchodilator response to an inhaled short acting beta2-agonist (albuterol/salbutamol) and an inhaled short acting anticholinergic (ipratropium) individually and…
- Trial name
- NCT01691482
- Testing
- Albuterol/salbutamol, Ipratropium
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 56 people
- Sponsor
- GlaxoSmithKline
Asthma
Family-Focused, Stress-Reduction Program to Improve the Health Care of Urban Children With Asthma
Stress and anxiety can negatively affect children with asthma. Reducing the stress of asthmatic children and their families may lead to improved asthma care and fewer asthma symptoms in the children.
- Trial name
- ASPIRE (NCT00384813)
- Testing
- Project ASPIRE Home-Based Family Intervention, Project ASPIRE Enhanced Treatment As Usual
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- Emory University
Pulmonary Disease, Chronic Obstructive
Study of Danirixin in Japanese Healthy Elderly Male Subjects
Danirixin is a selective chemokine receptor antagonist being developed as a potential anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT03136380
- Testing
- GSK1325756H
- Where
- 2 sites in Japan
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma
A Long-term Safety Study of QVM149 in Japanese Patients With Asthma
The purpose of this study is to provide long term safety data of QVM149 in Japanese patients with asthma for the registration of QVM149 in Japan.
- Trial name
- NCT03100825
- Testing
- QVM149
- Where
- 25 sites in Japan
- Volunteers
- 96 people
- Sponsor
- Novartis Pharmaceuticals
Cancer, Congestive Heart Failure
Expanding Access to Home-Based Palliative Care
This study will test the effectiveness of integrating an evidence-based model of home-based palliative (HBPC) within primary care clinics on patient and caregiver outcomes.
- Conditions
- Cancer, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease
- Trial name
- NCT03128060
- Testing
- Home-based palliative care, Enhanced usual care
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Southern California
Pulmonary Disease, Chronic Obstructive
Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
This is a multi-center, randomized, double-blind, parallel-group study. The FF/VI inhalation powder once daily and VI inhalation powder once daily will be evaluated in subjects with COPD over 156 weeks.
- Trial name
- NCT01957150
- Testing
- Fluticasone Furoate/Vilanterol, Vilanterol
- Where
- 45 sites in United States, Canada and 3 more
- Volunteers
- 283 people
- Sponsor
- GlaxoSmithKline
Asthma
A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate Asthma
This Phase III, randomized, double-blind, placebo-controlled, multicenter study will assess the efficacy and safety of lebrikizumab in adult patients with mild to moderate asthma treated with short-acting beta-agonist (SABA)…
- Trial name
- NCT02104674
- Testing
- Lebrikizumab, Montelukast
- Where
- 82 sites in United States, Brazil and 9 more
- Volunteers
- 313 people
- Sponsor
- Hoffmann-La Roche
Diabetic Neuropathic Pain, Chronic Low Back Pain
Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy
The purpose of the study is to determine whether the combination of the the three drugs gabapentin, duloxetine, and donepezil are effective in treating pain in people with diabetic neuropathy or patients with failed low back…
- Trial name
- NCT00619983
- Testing
- donepezil, duloxetine, donepezil 2.5 mg and duloxetine 30mg
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Wake Forest University
Chronic Obstructive Pulmonary Disease (COPD)
A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to measure the safety and tolerability of TD 4208, an investigational drug being developed to treat people with moderate to very severe COPD, compared to tiotropium.
- Trial name
- NCT02518139
- Testing
- TD-4208, Tiotropium
- Where
- United States
- Volunteers
- 1,060 people
- Sponsor
- Mylan Inc.
COPD
A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via the TWISTHALER® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study will evaluate the dose response relationship among four doses of indacaterol as well as placebo delivered via the TWISTHALER® device.
- Trial name
- NCT00557466
- Testing
- indacaterol, formoterol, short acting β2- agonist
- Where
- 75 sites in Argentina, Belgium and 15 more
- Volunteers
- 568 people
- Sponsor
- Novartis
Copd
Outcomes of Once-Daily ICS/LABA/LAMA + PRN Respiratory Therapy Treatments in Hospitalized Patients With COPD Exacerbations
This is a single-center, prospective, open-label study evaluating outcomes of TRELEGY ELLIPTA (fluticasone furoate 100 mcg, umeclidinium 62.5 mcg, and vilanterol 25 mcg inhalation powder) on PRN nebulized short-acting beta…
- Trial name
- Sundial-COPD (NCT05292053)
- Testing
- TRELEGY ELLIPTA 100Mcg-62.5Mcg-25Mcg/Actuation Powder for Inhalation
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Baylor Research Institute
Asthma
Triple in Asthma Dose Finding
Primary objective The primary objective was to evaluate the efficacy of a free combination of CHF 5259 at 3 dose levels plus Foster® 100/6 μg in a pMDI by comparison with Foster® 100/6 μg in terms of forced expiratory volume in…
- Trial name
- Triskel (NCT02127866)
- Testing
- CHF 5259 plus Foster 100/6 µg, Foster 100/6 µg (four puffs BID)
- Where
- 44 sites in Bulgaria, Germany and 4 more
- Volunteers
- 211 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Pulmonary Disease, Pulmonary Emphysema
Innovation in Pulmonary Rehabilitation
The purpose of this study was to compare the effect of exercise treatment combined with breathing retraining (a computerized feedback program), with exercise treatment combined with heliox (a helium and oxygen combination), with…
- Trial name
- NCT00123422
- Testing
- Breathing retraining, Heliox, Exercise
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- US Department of Veterans Affairs
Chronic Obstructive Pulmonary Disease
Effect of Oxygen-supply on 6-Minute-Walking-Distance of COPD III/IV-patients
The aim of this study is to investigate the six-minute-walking-distance of COPD-patients with breathing oxygen in comparison to breathing normal air.
- Trial name
- NCT00886639
- Testing
- 6MWT with oxygen, 6MWT with medical air
- Where
- Germany
- Volunteers
- 127 people
- Sponsor
- Schön Klinik Berchtesgadener Land
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.